Back to all assets

Kenvue KVUE

equity

Price History

$14.37$18.39$22.4$26.42
2023-05 · DCA start$25.09

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-45.6%-30.4%-15.2%0.0%
2023-052026-08 · -28.2%

Worst drawdown: −46%, peaking Jun 2023 and bottoming Oct 2025 — still unrecovered after 38 months.

DCA Backtest

Invested
$4,000
Value today
$3,775
Return
-5.6%
Months invested
40

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $4,187 today, so the real (inflation-adjusted) return is -9.8%.

Lump sum instead — $4,000 all at once in May 2023: $3,026 (-24.4%) — DCA came out ahead.

Worst timing — same monthly amount started at the all-time high (Jun 2023): $3,699 on $3,900 invested (-5.1%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 2023-05: -5.6%

About Kenvue

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. (Wikipedia)

It's a listed company categorised under consumer staples and personal care products, with a market cap of about $36.5B.

It rates Medium-High Risk at 2.6/5, meaning real but ordinary risk — the kind most mainstream assets carry, with some factors scoring poorly.

What pushes the score up: earnings quality (5.0/5) and leverage / financial (3.0/5).

Scoring well: liquidity at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-High Risk(2.6/5)80% rated

How these ratings work

Market / Volatility2.0/5 · weight 20%
  • Annualised volatility (3yr)3/532.1
  • Max drawdown from ATH2/545.6
  • Beta vs S&P 5001/50.46
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5382.3m
  • Float % of shares outstandingnot yet researched
Leverage / Financial3.0/5 · weight 20%
  • Debt / equitynot yet researched
  • Interest coverage (EBIT / interest)3/55.6
Earnings Quality5.0/5 · weight 15%
  • 3yr EPS volatility5/557.1
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory2.0/5 · weight 10%
  • Sector regulatory exposure2/5moderate

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.